Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.42 |
| ▸ | SDCBP | O00560 | 3/20 | 0.39 |
| ▸ | SDC2 | P34741 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | CSGALNACT1 | Q8TDX6 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | EEF2K | O00418 | 1/20 | 0.37 |
| ▸ | PLK1 | P53350 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 5/20 | 0.37 |
| ▸ | FLT4 | P35916 | 3/20 | 0.37 |
| ▸ | FLT3 | P36888 | 3/20 | 0.37 |
| ▸ | FRK | P42685 | 2/20 | 0.37 |
| ▸ | HIPK4 | Q8NE63 | 2/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13718977 | 1.00 | SLC1A3 (0.42) | SLC1A3SLC1A2SLC1A1SDCBPSDC2 | |
| SCHEMBL2178455 | 0.92 | LMNA (0.40) | SLC1A3SLC1A2SLC1A1MAPTAR | |
| SCHEMBL13718932 | 0.90 | SDCBP (0.41) | SLC1A3SLC1A2SLC1A1SDCBPSDC2 | |
| SCHEMBL2181732 | 0.90 | SDCBP (0.41) | SLC1A3SLC1A2SLC1A1SDCBPSDC2 | |
| SCHEMBL2179465 | 0.89 | KDR (0.42) | SDCBPSDC2KDR | |
| SCHEMBL13719378 | 0.89 | KDR (0.42) | SDCBPSDC2KDR | |
| SCHEMBL2179349 | 0.89 | CSGALNACT1 (0.43) | SDCBPSDC2MAPTDGAT1CSGALNACT1 | |
| SCHEMBL2176967 | 0.89 | CSGALNACT1 (0.43) | SDCBPSDC2MAPTDGAT1CSGALNACT1 | |
| SCHEMBL13719229 | 0.86 | MEN1 (0.41) | SLC1A3SLC1A2SLC1A1SDCBPSDC2 | |
| SCHEMBL2179316 | 0.86 | MEN1 (0.41) | SLC1A3SLC1A2SLC1A1SDCBPSDC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748426-B2 | Inhibitors of diacylglycerol acyl transferase | Piramal Enterprises Limited (IN) | 2014-06-10 | — | — | US | claimed |
| US-20120289505-A1 | INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE | Piramal Enterprises Limited (IN) | 2012-11-15 | — | — | US | claimed |
| US-8748426-B2 | Inhibitors of diacylglycerol acyl transferase | Piramal Enterprises Limited (IN) | 2014-06-10 | — | — | US | disclosed |
| US-20120289505-A1 | INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE | Piramal Enterprises Limited (IN) | 2012-11-15 | — | — | US | disclosed |
| EP-2519500-A1 | INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE | Piramal Healthcare Ltd. (IN) | 2012-11-07 | — | — | EP | disclosed |
| WO-2011080718-A1 | INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289505-A1 | INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE | DGAT1, DGAT2, LCAT | SLC1A3 2229/4885SLC1A2 2220/4885SLC1A1 2195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.